Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy
Open Access
- 16 April 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (6) , 2777-2783
Abstract
The aberrant expression of cell adhesion molecules is a hallmark of epithelial‐to‐mesenchymal transition, resulting in the transformation of cancer cells to a more aggressive phenotype. This study investigated the association between genetic variants in cell adhesion pathways and the prognosis of patients with prostate cancer following radical prostatectomy (RP). A total of 18 haplotype‐tagging single‐nucleotide polymorphisms (SNPs) in eight cancer‐related adhesion molecules were genotyped in 458 prostate cancer patients, followed by the replication of the top SNPs in an additional set of 185 patients. Log‐rank test and multivariate Cox regression analysis adjusted for covariates were used to evaluate associations with the risk of biochemical recurrence (BCR) after RP. In the discovery set, four SNPs in CDH2 were marginally associated with BCR. Among these, CDH2 rs643555C > T was found to be associated with BCR in the replication set. Patients with rs643555TT genotype had a significantly shorter BCR‐free survival compared with those with CC/CT genotypes in the combined analysis (adjusted hazard ratio 1.78, 95% confidence interval 1.19‐2.67, P = 0.005). Additional analyses revealed that rs643555T was associated with higher expression of CDH2, and upregulated CDH2 was correlated with tumor aggressiveness and shortened BCR‐free survival. In conclusion, rs643555C > T affects CDH2 expression, and thus influences BCR in localized prostate cancer patients treated with RP. CDH2 rs643555 may be a promising biomarker to identify patients at high risk of poor prostate cancer prognosis.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (104-2314-B-037-052-MY3, 105-2314-B-650-003-MY3, 106-2221-E-039-011-MY3, 106-2314-B-039-018, 107-2320-B-039-010)
- China Medical University (CMU107-S-24, CMU107-S-42)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH106-6R57)
- E-Da Hospital (EDPJ104059, EDPJ105054, EDPJ106038, EDAHP104053)
This publication has 24 references indexed in Scilit:
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- Genetic polymorphisms in oestrogen receptor‐binding sites affect clinical outcomes in patients with prostate cancer receiving androgen‐deprivation therapyJournal of Internal Medicine, 2011
- Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistanceNature Medicine, 2010
- N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancerEndocrine-Related Cancer, 2010
- Prognostic Significance of Prostate Cancer Susceptibility Variants on Prostate-Specific Antigen Recurrence after Radical ProstatectomyCancer Epidemiology, Biomarkers & Prevention, 2009
- SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studiesNucleic Acids Research, 2009
- Clinical and pharmacological phase I evaluation of Exherin™ (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumoursAnnals of Oncology, 2009
- High-risk prostate cancer in the United States, 1990–2007World Journal of Urology, 2008
- N-cadherin switching occurs in high Gleason grade prostate cancerThe Prostate, 2005
- Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transitionJournal of Cell Science, 2005